Search
Displaying 461–470 of 532 for “Retinitis pigmentosa”
-
My name is Raquel Alim and I am a legally blind artist from San Diego, California. I was diagnosed with Retinitis Pigmentosa at the young age of 12 and now in my 30’s and not letting blindness stop me from the things I love to do-like creating art.
-
Share Your Vision: Christine Exley
To help spread awareness during October Blindness Awareness Month, we’re inviting you to share your vision-loss journey through written word, audio or video as a part of our October “Share Your Vision” campaign. Visit www.FightingBlindness.org/ShareYourVision to learn more.
-
PRPH2 and Associated Retinal Diseases Workshop
Save the Date! The PRPH2 and AAssociated Retinal Diseases Workshop will be on March 29-31, 2023, at the Hilton La Jolla Torrey Pines in San Diego, CA.
-
“My dream career was to be a magazine or newspaper photographer,” recounts Ryck Lent. However, on a day in 1980, just before turning 30, he received a life-altering diagnosis: retinitis pigmentosa (RP). “After that, I knew my life was headed down a different path.”
-
Pat lives in Atlanta and has been working his way up in commercial photography for the last 8 years. He was recently diagnosed with retinitis pigmentosa at age 31.
-
Nicole Rubio was born in New York and graduated from the Museum School of Fine Arts, Boston. She migrated to the West Coast and was diagnosed with retinitis pigmentosa in 1978.
-
Colin was born in the small Western New York Community of Jamestown. His emersion into the arts started naturally, his mother was a designer and his father an art and antiques collector.
-
RD Fund Announces New Chair, and Expansion of Board of Directors
In the PressRD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair. Ophthalmology luminaries Jean Bennett, MD, PhD, Catherine Bowes Rickman, PhD, and José-Alain Sahel, MD, to join the board.
-
Live Stream: XLRP-Patient Focused Drug Development
The live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
XLRP-Patient Focused Drug Development
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
